| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| 10g |
|
||
| 25g |
|
| Targets |
Cinchonidine targets the malaria parasite, but its precise mechanism is not fully understood. It may also inhibit serotonin transporters. It has been shown to inhibit tumor cell growth. Its activity as a potassium channel blocker has also been noted.
|
|---|---|
| ln Vitro |
In vitro, Cinchonidine HCl inhibits the growth of tumor cells, particularly in cervical cancer (HeLa cells) and lung cancer (A-549 cells). It has antimalarial activity. It inhibits serotonin transporters. It affects phospholipid synthesis in Jurkat T cells.
|
| ln Vivo |
In vivo, Cinchonidine HCl has antimalarial activity. It has been used historically as an antimalarial agent. Its antitumor activity has also been investigated. Detailed in vivo efficacy data are limited.
|
| Enzyme Assay |
In vitro assays for Cinchonidine HCl typically measure its antimalarial activity against Plasmodium falciparum cultures. Parasite growth is assessed by measuring [3H]-hypoxanthine incorporation or by fluorescence-based methods. Its antitumor activity is assessed using cancer cell lines, and cell viability is measured using MTT assays.
|
| Cell Assay |
Cellular assays for Cinchonidine HCl are performed using cancer cell lines (e.g., HeLa, A-549). Cells are treated with the compound, and cell viability is assessed using MTT or CellTiter-Glo assays. Apoptosis is measured by Annexin V staining or caspase activity assays.
|
| Animal Protocol |
In vivo animal studies with Cinchonidine HCl are conducted in mouse models of malaria or cancer. The compound is administered orally or intraperitoneally. Parasitemia or tumor growth is monitored. Its efficacy in treating malaria or inhibiting tumor growth is evaluated.
|
| ADME/Pharmacokinetics |
Cinchonidine HCl is a cinchona alkaloid. Its molecular weight is 330.85 g/mol. For research use, it is typically dissolved in DMSO or water. Its half-life and metabolic profile have been characterized in pharmacokinetic studies.
|
| Toxicity/Toxicokinetics |
Cinchonidine HCl can cause side effects similar to other cinchona alkaloids, including cinchonism (headache, nausea, visual disturbances). It should be used with caution.
|
| Additional Infomation |
Cinchonidine HCl is a natural cinchona alkaloid with antimalarial activity. It is widely used as a chiral resolving agent and catalyst precursor in asymmetric synthesis. The compound has also been investigated for its antitumor activity. Cinchonidine HCl is not approved for clinical use as an antimalarial but is used in research.
|
| Molecular Formula |
C19H22N2O.HCL
|
|---|---|
| Molecular Weight |
330.85172
|
| Exact Mass |
330.15
|
| CAS # |
524-57-2
|
| Related CAS # |
485-71-2 524-54-9 (2HCl) 524-57-2 (HCl) 524-61-8 (sulfate) |
| PubChem CID |
21151043
|
| Appearance |
Typically exists as solid at room temperature
|
| Boiling Point |
489.4ºC at 760 mmHg
|
| Flash Point |
249.8ºC
|
| LogP |
3.904
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
23
|
| Complexity |
412
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C=CC1CN2CCC1CC2C(C3=CC=NC4=CC=CC=C34)O.Cl
|
| InChi Key |
IMUHWLVEEVGMBC-YYXOUSRLSA-N
|
| InChi Code |
InChI=1S/C19H22N2O.ClH/c1-2-13-12-21-10-8-14(13)11-18(21)19(22)16-7-9-20-17-6-4-3-5-15(16)17;/h2-7,9,13-14,18-19,22H,1,8,10-12H2;1H/t13-,14-,18-,19+;/m0./s1
|
| Chemical Name |
(R)-[(2S,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-quinolin-4-ylmethanol;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0225 mL | 15.1126 mL | 30.2252 mL | |
| 5 mM | 0.6045 mL | 3.0225 mL | 6.0450 mL | |
| 10 mM | 0.3023 mL | 1.5113 mL | 3.0225 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
